Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio, Inc. (NASDAQ: ACET) announced on November 30, 2022, the grant of inducement awards to three new employees, totaling 38,400 stock options with an exercise price of $18.18 per share. Additionally, Dr. Nancy Boman, the company's newly appointed Senior VP and Chief Regulatory Officer, received an award for 136,000 stock options at the same exercise price. The options will vest over four years, contingent on continued employment. These grants were made outside the stockholder-approved equity plans, aligning with Nasdaq rules.

Adicet Bio, Inc. (NASDAQ: ACET) has announced that CEO Chen Schor will present at the virtual JMP Securities Hematology and Oncology Summit on December 6, 2022, at 9:40 a.m. ET. The presentation will focus on the company’s advancements in allogeneic gamma delta T cell therapies for cancer. Investors can access the live audio webcast on Adicet's website, with a replay available for 30 days post-event. Adicet is focused on engineered T cells aimed at enhancing anti-tumor responses, showcasing their innovative approach in oncology.

Adicet Bio, Inc. (NASDAQ: ACET) has appointed Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will lead the regulatory strategy to enhance Adicet's gamma delta T cell therapy pipeline, including the initiation of a pivotal program for ADI-001 in the first half of 2023 and an IND application for ADI-925 in the second half of 2023. With nearly 30 years of experience in regulatory affairs, Dr. Boman previously held key roles at Encoded Therapeutics and AveXis, overseeing successful marketing applications.

Adicet Bio (ACET) reported promising safety and efficacy data for its lead candidate, ADI-001, targeting relapsed or refractory B-cell non-Hodgkin’s lymphoma. As of September 30, 2022, cash and cash equivalents were $282.7 million, providing a runway into the first half of 2025. R&D expenses rose to $16.6 million from $11.9 million year-over-year, while the net loss was $22.0 million, or $0.53 per share. The company plans to present updated data at the ASH Annual Meeting in December 2022 and outline new pipeline candidates at an R&D webcast on November 10, 2022.

Adicet Bio (ACET) announces promising preclinical data from four new gamma delta T cell therapy programs, showcased at the Society for Immunotherapy of Cancer's 37th Annual Meeting. The company plans to submit Investigational New Drug applications in the second half of 2023. CEO Chen Schor highlighted these developments as vital for advancing innovative cancer treatments. Adicet aims to enhance tumor targeting with its engineered therapies, which have shown increased efficacy in preclinical models. A detailed webcast is scheduled for November 10, 2022, to discuss these findings further.

Adicet Bio announced promising results from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell Non-Hodgkin's lymphoma. As of July 15, 2022, the therapy showed a 78% overall response rate and a 100% complete response rate in patients with prior CAR T therapy. No severe adverse events were reported, indicating a favorable safety profile. Adicet plans to present further data at the ASH Annual Meeting on December 10, 2022, and a webcast to discuss recent findings is scheduled for December 11, 2022.

Adicet Bio (NASDAQ: ACET) will have its CEO Chen Schor present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 7:25 a.m. GMT. Interested parties can access the live audio webcast on Adicet Bio’s website, and an archived replay will be available for 30 days post-event.

Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer, aiming to enhance anti-tumor immune response.

Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on October 31, 2022, to 12 new hires under its 2022 Inducement Plan. The awards include non-qualified stock options to purchase 251,600 shares of common stock at an exercise price of $16.49 per share. Vesting will occur over four years, with one-fourth vesting after one year and the remainder in thirty-six equal monthly installments, contingent on continued employment. The inducement plan was approved by an independent board committee.

Adicet Bio (NASDAQ: ACET) will host an R&D webcast on November 10, 2022, at 9:00 AM EST, providing a pipeline overview. The company will showcase four preclinical abstract presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting on November 8-12, 2022, in Boston, MA. Topics include novel immune therapies targeting prostate cancer and CD70+ cancers. The abstracts will be available in the Journal for ImmunoTherapy of Cancer on November 7, 2022.